TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Small-cell lung cancer (SCLC) is an aggressive subtype of lung cancer, the leading cause of cancer-related deaths.
• TP53 mutations are common in SCLC, but their specific role (missense vs. loss) in pathogenesis is debated.
• Understanding the mechanisms of TP53 mutations in SCLC is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the role of common TP53 missense mutants (R270H, R172H) combined with RB1 loss in SCLC development.
• To determine whether TP53 mutants function through loss-of-function or gain-of-function mechanisms in lung carcinogenesis.
• To evaluate the efficacy of targeted and cytotoxic therapies in preclinical models of SCLC.

Main Methods:

• Generated genetically engineered mouse models with lung epithelial expression of specific TRP53 mutants (R270H, R172H) and RB1 loss.
• Assessed tumor initiation, progression, and metastatic potential in these mouse models.
• Evaluated therapeutic responses to rapamycin and cisplatin/etoposide in both mouse models and corresponding tumor cell cultures.

Main Results:

• TP53 mutants (R270H, R172H) plus RB1 loss selectively induced SCLC and large cell neuroendocrine carcinoma (LCNEC) with rapid, lethal progression.
• TRP53 mutants primarily act through loss-of-function mechanisms.
• Therapeutic responses were discordant between in vitro cultures and in vivo models; cisplatin/etoposide prolonged survival but led to chemoresistance, influenced by specific TP53 mutants.

Conclusions:

• TP53 mutants play a causative role in the development of chemoresistant SCLC.
• Preclinical models developed here are valuable for testing novel therapeutics against refractory lung cancer.
• Assessing therapeutic response at the organismal level is critical for predicting clinical efficacy.